{"id":"W3167858868","doi":"10.1200/jco.2021.39.15_suppl.4515","title":"Safety and efficacy outcomes with nivolumab plus ipilimumab in patients with advanced renal cell carcinoma and brain metastases: results from the CheckMate 920 trial.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Bristol-Myers Squibb Canada","keywords":"Medicine; Ipilimumab; Internal medicine; Nivolumab; Clinical endpoint; Renal cell carcinoma; Tolerability; Clinical trial; Brain metastasis; Oncology; Adverse effect; Surgery; Cancer; Immunotherapy; Metastasis","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002111241,0.0005291082,0.0009372079,0.0002667303,0.0002591291,0.001074333,0.000596999,0.0008202638,0.001991595],"category_scores_gemma":[0.00159953,0.0002010367,0.001460084,0.0003842302,0.0003682117,0.0004703814,0.0003496945,0.001276269,0.0003374349],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001074798,"about_ca_system_score_gemma":0.00100361,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001520454,"about_ca_topic_score_gemma":0.003989753,"domain_scores_codex":[0.999481,0.0002420626,0.00003748135,0.0001029973,0.0000759055,0.00006057384],"domain_scores_gemma":[0.999038,0.0001814961,0.0003300557,0.00006616986,0.00006980556,0.0003146292],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7801863,0.006335336,0.07021134,0.00242366,0.009036553,0.0002201872,0.0001902488,0.003354534,0.01077527,0.000301062,0.01114105,0.1058245],"study_design_scores_gemma":[0.5111447,0.174311,0.2819676,0.0004036013,0.009849381,0.0008580221,0.0001121516,0.003998025,0.003602733,0.0006879272,0.01295366,0.0001112],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9823906,0.0100082,0.0002027296,0.0004107645,0.00009752215,0.0006124093,0.003416453,0.00004969931,0.00281162],"genre_scores_gemma":[0.9900768,0.001699775,0.0003657958,0.0006775909,0.0001323216,0.0004850074,0.005755287,0.0000121188,0.0007952307],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002111241,"threshold_uncertainty_score":0.01116544,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05059253940692358,"score_gpt":0.3618151297599955,"score_spread":0.3112225903530719,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}